Back to Archived Journals » Clinical Oncology in Adolescents and Young Adults » Volume 2
New treatment options for nonmetastatic osteosarcoma: focus on mifamurtide in adolescents
Authors Huh W, Egas Bejar D, Anderson P
Received 22 June 2012
Accepted for publication 21 August 2012
Published 6 September 2012 Volume 2012:2 Pages 1—6
DOI https://doi.org/10.2147/COAYA.S27725
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Winston W Huh, Daniela Egas-Bejar, Peter M Anderson
Division of Pediatrics, The Children's Cancer Hospital of the University of Texas MD Anderson Cancer Center, Houston, TX, USA
Abstract: New treatments are needed to improve the clinical outcome for patients with osteosarcoma. Liposomal muramyl tripeptide phosphatidylethanolamine (mifamurtide) is a synthetic peptidoglycan component packaged in multilamellar liposomes. Mifamurtide has been demonstrated to induce recruitment and activation of macrophages and monocytes of the host innate immune system, which leads to antitumoricidal activity. Early clinical trials have demonstrated the safety and tolerability of mifamurtide combined with chemotherapy, and one major study has demonstrated an overall survival benefit in patients with newly diagnosed nonmetastatic osteosarcoma. This review summarizes the mechanism of action, clinical results, and the optimal biologic dose, and raises potential questions for future development of mifamurtide.
Keywords: osteosarcoma, childhood cancer, adolescent, sarcoma, immunotherapy, bone
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.